Public Employees Retirement Association of Colorado trimmed its holdings in Zoetis Inc. (NYSE:ZTS) by 0.6% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,325,848 shares of the company’s stock after selling 7,599 shares during the quarter. Zoetis makes up about 1.1% of Public Employees Retirement Association of Colorado’s portfolio, making the stock its 14th biggest position. Public Employees Retirement Association of Colorado owned 0.28% of Zoetis worth $247,085,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also modified their holdings of ZTS. Meridian Wealth Partners LLC purchased a new position in Zoetis during the 1st quarter worth $26,000. Sound Income Strategies LLC increased its holdings in Zoetis by 1,069.2% during the 2nd quarter. Sound Income Strategies LLC now owns 152 shares of the company’s stock worth $28,000 after purchasing an additional 139 shares during the period. WealthShield Partners LLC increased its holdings in Zoetis by 60.2% during the 2nd quarter. WealthShield Partners LLC now owns 165 shares of the company’s stock worth $31,000 after purchasing an additional 62 shares during the period. Key Financial Inc increased its holdings in Zoetis by 72.2% during the 2nd quarter. Key Financial Inc now owns 167 shares of the company’s stock worth $34,000 after purchasing an additional 70 shares during the period. Finally, Harbour Investments Inc. purchased a new position in Zoetis during the 1st quarter worth $43,000. Hedge funds and other institutional investors own 89.53% of the company’s stock.
ZTS stock traded up $3.83 during midday trading on Thursday, reaching $201.29. The stock had a trading volume of 26,244 shares, compared to its average volume of 1,778,479. The stock has a market cap of $95.40 billion, a PE ratio of 49.92, a P/E/G ratio of 3.31 and a beta of 0.64. The company has a debt-to-equity ratio of 1.51, a quick ratio of 2.51 and a current ratio of 3.37. The firm has a fifty day simple moving average of $202.11 and a two-hundred day simple moving average of $187.69. Zoetis Inc. has a 52-week low of $141.41 and a 52-week high of $210.10.
In other Zoetis news, EVP Roman Trawicki sold 4,497 shares of Zoetis stock in a transaction dated Friday, October 1st. The stock was sold at an average price of $194.14, for a total transaction of $873,047.58. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Roxanne Lagano sold 1,315 shares of Zoetis stock in a transaction dated Thursday, September 23rd. The shares were sold at an average price of $202.17, for a total value of $265,853.55. The disclosure for this sale can be found here. Insiders sold a total of 53,815 shares of company stock valued at $10,850,755 in the last 90 days. 0.17% of the stock is currently owned by company insiders.
Several analysts have issued reports on ZTS shares. Raymond James cut Zoetis from an “outperform” rating to a “market perform” rating in a research report on Friday, July 16th. Argus increased their target price on Zoetis from $195.00 to $225.00 and gave the company a “buy” rating in a research report on Wednesday, August 25th. Cantor Fitzgerald increased their target price on Zoetis from $210.00 to $238.00 and gave the company an “overweight” rating in a research report on Tuesday, July 13th. Credit Suisse Group increased their target price on Zoetis from $206.00 to $230.00 and gave the company an “outperform” rating in a research report on Monday, August 9th. Finally, Barclays increased their target price on Zoetis from $208.00 to $235.00 and gave the company an “overweight” rating in a research report on Friday, August 6th. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, Zoetis has a consensus rating of “Buy” and an average price target of $199.82.
Zoetis, Inc discovers, develops, and manufactures a portfolio of animal health medicines and vaccines. The firm operates through the following segments: United States &International. Its products are complemented by diagnostic products, genetic tests, bio devices, and services. These are designed to meet the needs of veterinarians and the livestock farmers and companion animal.
Featured Story: What are Institutional Investors?
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.